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Abstract 
Purpose: The aim of the study was to assess the validity, reliability and sensitivity of the FACT-
P (Version 4) in Chinese males with prostate cancer.  
Methods: Construct validity was assessed using Spearman’s correlation test against the 12-item 
Short Form Health Survey (SF-12v2).  Internal consistency and test-retest reliability was 
assessed using Cronbach’s α coefficient and intra-class correlation coefficient, respectively. 
Sensitivity was determined by performing known group comparisons by independent t-test. 
Results: FACT-P subscale scores had a moderate correlation with the corresponding SF-12v2 
domain score that conceptually measures the similar construct providing evidence for adequate 
construct validity. Internal consistency was acceptable (α: 0.687-0.900) for all subscales aside 
from the Prostate Cancer Subscale (α: 0.505) and Trial Outcome Index (α: 0.562). FACT-P 
subscale and total scores showed good test-retest reliability (range: 0.753-0.913).  All total scales 
and most of the subscales were sensitive in detecting differences between subjects with different 
levels of functional impairment but not different cancer stages or levels of prostate-specific 
antigen. 
Conclusions: The measure is a valid and reliable measure to assess the health-related quality of 
life of Chinese males with prostate cancer. The FACT-P is sensitive to detect difference between 
subjects with varying functional status.   
Word Count: 195 
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Manuscript Text 
 
Introduction 
Prostate cancer is the second commonest cancer in adult males worldwide[1]. As patients with 
prostate cancer had poorer well-being[2-4], assessment of health-related quality of life (HRQOL) 
can be used clinically to assist healthcare providers identify individuals who may be at risk of 
poor well-being, to help guide treatment planning, and to evaluate the effectiveness of 
interventions[5].  
The Functional Assessment of Cancer Therapy-General (FACT-G)[6] is a well-established and 
validated instrument which has been widely used to measure HRQOL in cancer patients[7-9].  
One limitation of the FACT-G is that it only evaluates generically the impact of cancer on 
HRQOL without consideration of the specific impacts which cancer may have on HRQOL. In 
response to this, the Functional Assessment of Cancer Therapy-Prostate (FACT-P) was 
developed to more specifically capture the HRQOL relevant to prostate cancer patients. The 
FACT-P is a modification of the FACT-G to include a Prostate Cancer Subscale[10; 11]. 
However, there is still a lack of evidence on the psychometrics of the FACT-P in Chinese 
patients with prostate cancer. 
Objective of the present study was to assess the validity, reliability and sensitivity of the FACT-P 
in Chinese patients with prostate cancer.  
Methods  
Subjects and Setting  
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Convenience sampling of patients with histological proof of prostate cancer were recruited 
between May 2013 and January 2014 in a major teaching hospital in Hong Kong.  Patients were 
excluded if they could not understand or speak Cantonese, refused to participate or were too ill to 
give consent.  
Subjects who consented were subsequently asked to answer a structured questionnaire which 
consisted of the traditional Chinese version of FACT-P (version 4), the Chinese Hong Kong 
version of Short Form-12 Health Survey version 2 (SF-12v2) and questions on socio-
demographics.  
Clinical data for each subject including the undertaken of androgen deprivation therapy, 
Prostate-Specific Antigen (PSA) level, the stage of cancer as classified by 7th Edition of TNM 
American Joint Committee on Cancer and the Karnofsky Performance status (KPS)[12], were 
retrieved from subject’s medical record.   
All subjects were contacted again through telephone within two weeks after their baseline 
interview to assess test-retest reliability. 
Study Instruments  
Functional Assessment of Cancer Therapy-Prostate (FACT-P) 
The traditional Chinese version of FACT-P (version 4) has 39 items grouped into five subscales: 
seven items related to Physical Well-Being (PWB), seven items related to Social/Family Well-
Being (SWB), six items related to Emotional Well-Being (EWB), seven items related to 
Functional Well-Being (FWB) and twelve items belonging to the Prostate Cancer Subscale 
(PCS). Individual subscale scores are calculated by summation of the valued item responses, 
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with higher scores indicating better HRQOL. The PWB, FWB and PCS subscales are combined 
to yield the FACT-P Trial Outcome Index (TOI). The sum of PWB, SWB, EWB and FWB 
subscale scores gives the overall FACT-G score with a range from 0 to 108. The PCS score is 
combined with the overall FACT-G score to form the overall FACT-P score with a range from 0 
to 156.  
Short Form-12 Health Survey version 2 (SF-12v2) 
The Chinese (HK) SF-12v2 has been validated and normed on the Hong Kong Chinese adults[13; 
14]. The SF-12v2 has eight domain scales and two summary scales, with higher scores indicating 
better HRQOL.  
Statistical Analysis 
The construct validity of the FACT-P was assessed using spearman’s correlation test against the 
SF-12v2 domain scores holding similar constructs.  
The internal consistency was assessed by Cronbach’s alpha using a value ≥ 0.7 to indicate 
adequate internal consistency[15]. Test-retest reliability was assessed by examining the intra-
class correlation coefficient (ICC) over the 2-week period. An ICC of ≥ 0.7 was used to indicate 
good reproducibility[16].  
The sensitivity of the FACT-P was determined by performing known group comparisons by 
independent t-test and effect size. Cohen's effect size was calculated as the difference between 
mean scores, divided by pooled SD.  Known clinical groups were (i) early cancer stage I/II 
versus late cancer stage III/IV; (ii) KPS ≤80 versus KPS>80 and (iii) PSA<10ng/ml versus 
PSA≥10ng/ml. It was hypothesized that patients with more severe cancer staging, lower KPS, 
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higher PSA level or androgen deprivation therapy were associated with poorer HRQOL as 
measured by the FACT- P instrument. 
Data analyses were conducted using SPSS Windows 21.0 (IBM SPSS Inc., Chicago, IL, USA). 
P-value<0.05 was statistically significant. 
Results 
Baseline characteristics of study subjects and results of construct validity are shown in Table 1 
and Table 2, respectively. It was observed that the PWB, SWB, EWB and FWB subscale had a 
moderate correlation (r: 0.44–0.69) with the corresponding SF-12v2 subscale that conceptually 
held the similar construct.  
The reliability of the FACT-P is shown in table 3. The Cronbach’s alpha coefficient exceeded 
0.7 in the PWB, SWB, EWB and FWB subscale. The Cronbach’s alpha coefficients were just 
short of 0.7 in FACT-G and FACT-P total scale, still acceptable, according to Churchill’s 
benchmark[17].  The ICCs of all subscales, FACT-G total scale, TOI and FACT-P total scale 
exceeded 0.7.  
The sensitivity of the FACT-P in differentiating known clinical groups is shown in Table 4. The 
FACT-P was not able to detect differences between subjects with different cancer stages (I/II vs. 
III/IV) or subjects with different PSA levels. Statistically significant differences were detected 
between subjects with KPS≤80 and those with KPS>80 by PWB, SWB, FWB, prostate cancer 
subscale, FACT-G total scale, TOI, and FACT-P total scale.  Moreover, patients with androgen 
deprivation therapy had statistically worse FWB score than those without. 
Discussion 
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This study reported the psychometric properties of the FACT-P in Chinese patients with prostate 
cancer. Of note, the present study was not the first one to report the results of psychometric 
testing of prostate cancer-specific HRQOL instrument among Chinese patients with prostate 
cancer.   
This study contributed further insights into the floor and ceiling effects of the FACT-P, 
identifying that a significant ceiling effect was evident in the PWB and EWB subscales. One 
interpretation is that physical well-being and emotional well-being are not negatively affected by 
prostate cancer in our study population.  A previous study conducted in Singapore also found a 
significant ceiling effect in PWB and EWB subscales in Chinese patients with gastric cancer[18]. 
Clinicians and researchers should therefore interpret the PWB and EWB subscale scores with 
caution, especially when evaluating interventions for patients with prostate cancer as 
interventions may appear to be ineffective due to the significant ceiling effects. 
The PWB, SWB and FWB subscales, TOI, FACT-G and FACT-P total scale were able to 
differentiate patients with different degrees of functional impairment. These findings also 
revealed that there are moderate differences in HRQOL between patients with varying functional 
impairment.  This finding was in line with a previous study which suggested that the level of 
functional impairment as measured by the KPS had a significant association with HRQOL[19]. 
Moreover, the FWB subscale score was able to differentiate patients treated with and without 
androgen deprivation therapy. The change in functional well-being due to androgen deprivation 
therapy was supported by previous studies[20-22]. The measure was not able to discriminate 
known clinical groups, by cancer staging or PSA level.  It appeared that the stage of cancer and 
PSA level did not significantly affect the HRQOL of our study subject with prostate cancer.  
This was contrary to a previous study of Chinese patients which found that subjects with stage 
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III/VI prostate cancer had poorer HRQOL in the physical functioning, role functioning and social 
functioning domains as measured by QLQ-C30 than those with stage I/II prostate cancer[23].  A 
further examination of the inter-relationships between known clinical groups and HRQOL is 
warranted. 
In summary, the FACT-P demonstrated satisfactory psychometric properties in terms of validity, 
reliability and sensitivity in Chinese patients with prostate cancer. Our finding supported the 
applicability of the instrument to evaluate the HRQOL and its associations with clinical 
interventions on Chinese patients with prostate cancer. 
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Tables 
Table 1. Baseline Characteristics of Prostate Cancer Patients 
  
  
  
     Demographic Total (N=291)   Clinical Total (N=291) 
Characteristics N %   Characteristics N % 
Age (years, Mean±SD) 74.92 ± 8.61 
 
PSA   Education     
<0.1ng/ml 109 37.46 % 
 
No formal schooling 46 15.81 % 
  
≥0.1 & <10ng/ml 121 41.58 % 
 
Primary 98 33.68 % 
  
≥10ng/ml 39 13.40 % 
 
Secondary 90 30.93 % 
  
Unknown 22 7.56 % 
 
Tertiary or above 53 18.21 % 
 
AJCC Cancer Staging   
 
Unknown 4 1.37 % 
  
I 58 19.93 % 
Marital Status     
II 75 25.77 % 
 
Married 222 76.29 % 
  
III 31 10.65 % 
 
Single 17 5.84 % 
  
IV 112 38.49 % 
 
Separated, divorced or 
widower 
48 16.49 % 
  
Unknown 15 5.15 % 
 
Unknown 4 1.37 % 
 
Distant metastasis 59 20.27 % 
Currently Working    
KPS   
 
Yes 25 8.59 % 
  
Mean±SD 91.39 ± 12.50 
 
No 262 90.03 % 
  
≤70 23 7.90 % 
 
Unknown 4 1.37 % 
  
80 34 11.68 % 
Monthly income (HKD$)     
90 64 21.99 % 
 
≤20,000 238 81.79 % 
  
100 138 47.42 % 
 
>20,000 49 16.84 % 
  
Unknown 32 11.00 % 
  Unknown 4 1.37 %   Androgen deprivation  116 39.86 %  
Note:        SD=standard deviation; PSA=Prostate-specific antigen; KPS=Karnofsky performance status; 
AJCC=American Joint Committee on Cancer  
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Table 2. Spearman’s Correlation Coefficients of Subscales and Total Scores between the FACT-P and SF-12 
Instruments 
             SF-12v2 Domain and Summary Scores 
Subscale/Total scale PF RP BP GH VT SF RE MH PCS MCS 
Physical Well-being .620 .643 .647 .639 .482 .605 .471 .455 .646 .274 
Social Well-being .363 .448 .337 .410 .453 .440 .324 .414 .375 .329 
Emotional Well-being .187 .291 .238 .382 .474 .376 .672 .690 .110 .712 
Functional Well-being .587 .660 .514 .685 .681 .649 .602 .591 .576 .478 
Prostate Cancer Subscale .599 .663 .614 .662 .534 .563 .506 .517 .629 .354 
FACT-G total score .572 .664 .547 .682 .662 .661 .646 .675 .555 .554 
TOI .675 .738 .654 .754 .637 .668 .595 .603 .688 .426 
FACT-P total score .611 .699 .597 .718 .659 .664 .628 .674 .607 .517 
Note: 
          FACT-P=Functional Assessment of Cancer Therapy-Prostate; FACT-G=Functional Assessment of Cancer 
Therapy-General; TOI=Trial Outcome Index; PF=physical functioning; RP=role physical; BP=bodily pain; 
GH=general health; VT=vitality; SF=social functioning; RE=role emotional; MH=mental health; 
PCS=Physical Composite Scale; MCS=Mental Composite Scale; 
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Table 3. Internal Consistency Reliability and Test-retest Reliability of FACT-P Subscales and Total Scores 
  
    
                 Cronbach's Alpha   Intra-class correlation 
Subscale/Total score   Mean 
Standard 
deviation 
Floor 
(%) 
Ceiling 
(%) n Estimate 95% CI  n Estimate 95% CI 
Physical Well-being 7 items 24.63 3.64 0.00 25.43 291 .798 0.761 0.832 
 
191 .753 0.684 0.808 
Social Well-being 7 items* 19.62 5.18 0.34 6.19 291 .891 0.870 0.909 
 
191 .778 0.715 0.828 
Emotional Well-being 6 items 21.08 3.76 0.34 23.71 290 .704 0.648 0.754 
 
191 .806 0.750 0.851 
Functional Well-being 7 items 19.72 5.38 0.34 9.28 290 .900 0.882 0.917 
 
191 .878 0.841 0.907 
Prostate Cancer Subscale 12 items 35.82 6.61 0.00 0.00 289 .505 0.416 0.585 
 
191 .878 0.841 0.907 
FACT-G total score 27 items* 85.04 13.90   289 .691 0.638 0.741 
 
191 .900 0.869 0.924 
TOI 26 items 80.17 13.74   289 .562 0.485 0.631 
 
191 .893 0.860 0.918 
FACT-P total score 39 items* 120.94 19.22   288 .687 0.633 0.736   190 .913 0.886 0.934 
Note: 
 
    
         FACT-P=Functional Assessment of Cancer Therapy-Prostate; FACT-G=Functional Assessment of Cancer Therapy-General; TOI=Trial Outcome 
Index 
* One item in Social Well-being is optional item 
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Table 4. Sensitivity to differentiate known clinical groups 
 
          AJCC Cancer staging 
 
Stage I/II (n=133)   Stage III/IV (n=143)     
Subscale/Total score Mean SD 
 
Mean SD P-value ES 
Physical Well-being 24.36 3.78   24.80 3.46 0.318 -0.12 
Social Well-being 19.02 5.80  20.04 4.62 0.105 -0.19 
Emotional Well-being 21.10 3.85  21.02 3.65 0.860 0.02 
Functional Well-being 19.29 5.80  19.83 5.07 0.416 -0.10 
Prostate Cancer Subscale 35.22 6.86  36.22 6.31 0.204 -0.15 
FACT-G total score 83.77 15.29  85.68 12.63 0.257 -0.14 
TOI 78.87 14.51  80.85 13.02 0.234 -0.14 
FACT-P total score 119.13 20.84   121.90 17.67 0.234 -0.14 
 
KPS 
 
≤80 (n=57)   >80 (n=202)     
 
Mean SD 
 
Mean SD P-value ES 
Physical Well-being 23.44 4.44  25.00 3.32 0.004 -0.40 
Social Well-being 17.49 4.99  20.13 4.92 <0.001 -0.53 
Emotional Well-being 20.89 4.53  21.03 3.58 0.809 -0.03 
Functional Well-being 17.12 5.98  20.29 5.06 <0.001 -0.57 
Prostate Cancer Subscale 33.63 7.24  36.41 6.21 0.004 -0.41 
FACT-G total score 78.95 16.67  86.46 12.77 <0.001 -0.51 
TOI 74.19 16.32  81.71 12.51 <0.001 -0.52 
FACT-P total score 112.82 23.05   122.87 17.58 <0.001 -0.49 
 
PSA 
 
<10ng/ml (n=230)   ≥10ng/ml (n=38)     
 
Mean SD 
 
Mean SD P-value ES 
Physical Well-being 24.49 3.72  25.11 3.21 0.339 -0.18 
Social Well-being 19.67 5.27  19.11 4.88 0.543 0.11 
Emotional Well-being 21.13 3.74  21.03 3.49 0.869 0.03 
Functional Well-being 19.87 5.58  18.00 4.69 0.052 0.36 
Prostate Cancer Subscale 35.80 6.88  36.13 4.87 0.777 -0.06 
FACT-G total score 85.16 14.41  83.25 11.61 0.437 0.15 
TOI 80.16 14.42  79.24 10.65 0.705 0.07 
FACT-P total score 121.06 20.01   119.38 15.04 0.620 0.09 
 
Androgen deprivation therapy 
 
No (n=175)   Yes (n=116)   
 
 
Mean SD 
 
Mean SD P-value ES 
Physical Well-being 24.69 3.60  24.49 3.72 0.734 0.05 
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Social Well-being 19.89 5.40  19.67 5.27 0.267 0.04 
Emotional Well-being 21.04 3.92  21.13 3.74 0.849 -0.02 
Functional Well-being 20.27 5.50  19.87 5.58 0.032 0.07 
Prostate Cancer Subscale 35.80 6.73  35.80 6.88 0.950 0.00 
FACT-G total score 85.89 14.33  85.16 14.41 0.201 0.05 
TOI 80.76 13.93  80.16 14.42 0.370 0.04 
FACT-P total score 121.70 19.84   121.06 20.01 0.411 0.03 
Note: 
       KPS=Karnofsky performance status; PSA=Prostate-specific antigen; TOI=Trial Outcome 
Index; SD=Standard deviation; ES=Effect Size 
Cohen's effect size was calculated as the difference between mean scores, divided by pooled 
SD 
